Results 11 to 20 of about 1,005 (173)

Effects of Histamine H3 Receptor Antagonist/Inverse Agonist Pitolisant on Temporal Prediction, Spatial Switching, and Spontaneous Locomotion in Mice [PDF]

Neuropsychopharmacology Reports
Histamine receptors contribute to a wide range of brain functions, including arousal, motivation, attention, and memory, but their causal involvement in switching behavior remains insufficiently understood.
Shohei Kaneko, Kazuko Hayashi, Kota Yamada, Koji Toda   +3 more
doaj   +3 more sources

Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease [PDF]

Translational Psychiatry
Histamine H3 receptor (H3R) antagonists regulate histamine release that modulates neuronal activity and cognitive function. Although H3R is elevated in Alzheimer’s disease (AD) patients, whether H3R antagonists can rescue AD-associated neural impairments
Yang Zou, Linhan Yang, Jiahui Zhu, Jihua Fan, Hanrun Zheng, Xiang Liao, Zhiqi Yang, Kuan Zhang, Hongbo Jia, Arthur Konnerth, Yan-jiang Wang, Chunqing Zhang, Yun Zhang, Sunny C. Li, Xiaowei Chen   +14 more
doaj   +3 more sources

Pitolisant disrupts memory consolidation and hippocampal synaptic plasticity: Impaired excitability and long-term potentiation in the CA1 area [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): The histaminergic system plays a vital role in memory function, but the underlying cellular and circuit mechanisms remain poorly understood.
Siamak Beheshti, Adeleh Badiyifard, Zahra Badiei Darani, Mansour Azimzadeh, Alireza Halabian   +4 more
doaj   +2 more sources

Pitolisant Inhibits Alcohol Drinking and Improves Withdrawal Negative Affect Through Lateral Habenula Histaminergic Signaling in Mice [PDF]

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
Pitolisant, an FDA‐approved H3R antagonist, counteracts the rewarding and sedative effects of ethanol, reduces alcohol intake, and alleviates the negative affect during withdrawal. This might occur via the antagonism of presynaptic autoreceptors and heteroreceptors H3Rs in the lateral habenula, thereby activating the H2R/p‐CREB/BDNF signaling and ...
Yan Zhao, Yixin Fu, Tianhao Liu, Zanhao Yang, Zhengzhong Yang, Bingqing Chen, Lipeng Zhou, Juntao Yang, Duo Chen, Xiaojiao Han, Ying Tang, Jiang‐Hong Ye, Chao‐Yu Miao, Rao Fu   +13 more
wiley   +2 more sources

Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report [PDF]

Nature and Science of Sleep, 2020
Gaia Pellitteri,1,2 Pierluigi Dolso,1 Mariarosaria Valente,1,2 Gian Luigi Gigli1– 3 1Clinical Neurology Unit, Department of Neurosciences, Udine University Hospital, Udine, Italy; 2Department of Medicine (DAME), University of Udine, Udine, Italy ...
Pellitteri G, Dolso P, Valente M, Gigli GL   +3 more
doaj   +2 more sources

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy

Drug Design, Development and Therapy, 2018
Andrea Romigi,1 Giuseppe Vitrani,1 Temistocle Lo Giudice,1 Diego Centonze,1,2 Valentina Franco3 1IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli (IS), Italy; 2Department of System Medicine, University of Rome Tor Vergata Rome, Italy; 3IRCCS ...
Romigi A, Vitrani G, Lo Giudice T, Centonze D, Franco V   +4 more
doaj   +2 more sources

Acute hypobaric hypoxia attenuates the anti-fatigue effects of pitolisant by downregulating the expression of organic cation transporter 1 and P-glycoprotein [PDF]

Frontiers in Pharmacology
ObjectiveThis study investigates the effects of acute hypobaric hypoxia (HH) on the anti-fatigue properties of pitolisant and explores the underlying mechanisms.
Gang Zhao, Yajuan Li, Mengyuan Liu, Mengyuan Liu, Wei Chang, Hui Shen, Junhui Xue, Junhui Xue, Junhui Xue, Fengzhou Liu, Fengzhou Liu   +10 more
doaj   +2 more sources

Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP : Randomised phase 3 study [PDF]

J Sleep Res
International audienceSummary Obstructive sleep apnea (OSA) syndrome commonly leads to excessive daytime sleepiness (EDS). Pitolisant, a selective histamine‐3 receptor antagonist, is efficacious at doses up to 20 mg once daily in OSA treated or not with ...
Dauvilliers, Yves, Verbraecken, Johan, Lehert, Philippe, Randerath, Winfried, Bonsignore, Maria, Lecomte, Jeanne‐marie, Barbé, Ferran, Schwartz, Jean‐charles, Georgiev, Ognian, Craig, Sonya Elizabeth, Tiholov, Rumen, Asin, Jerryl, Caussé, Christian, Pépin, Jean‐louis   +13 more
core   +4 more sources

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis [PDF]

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +2 more sources

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]

EClinicalMedicine
Summary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin, Philippe Lehert, Raoua Ben Messaoud, Marie Joyeux-Faure, Christian Caussé, Jerryll Asin, Ferran Barbé, Maria R. Bonsignore, Winfried Randerath, Johan Verbraecken, Sonya Craig, Yves Dauvilliers   +11 more
doaj   +2 more sources